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Abstract
Objectives: Assessments of health technologies increasingly include economic evaluations conducted
alongside clinical trials. One particular concern with economic evaluations conducted alongside clinical
trials is the generalizability of results from one setting to another. Much of the focus relating to this topic
has been on the generalizability of results between countries. However, the characteristics of clinical
trial design require further consideration of the generalizability of cost data between centers within a
single country, which could be important in decisions about adoption of the new technology.
Methods: We used data from a multicenter clinical trial conducted in the United Kingdom to assess the
degree of variation in costs between patients and between treatment centers and the determinants of
the degree of such variation.
Results: The variation between patients was statistically significant for both the experimental and con-
ventional treatments. However, the degree of variation between centers was only statistically significant
for the experimental treatment. Such variation appeared to be a result of hospital practice, such as pay-
ment mechanisms for staff and provision of hostel accommodation, rather than variations in physical
resource use or substantive differences in cost structure.
Conclusions: Multicenter economic evaluations are necessary for determining the variations in hospital
practice and characteristics that can in turn determine the generalizability of study results to other
settings. Such analyses can identify issues that may be important in adopting a new health technology.
Analysis is required of similar large multicenter trials to confirm these conclusions.
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Assessments of health technologies usually include an economic evaluation. The num-
ber of economic evaluations conducted alongside clinical trials continues to grow (e.g.,
5;10;18). In part, this may be linked to the growing interest of governments in economic
data, which includes requirements for economic data in support of decisions on drug pricing
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and reimbursement and suggestions that clinical trials of nonpharmaceutical therapies con-
sider economic issues relating to the choice of therapy (3;12). Government guidelines for
economic evaluation stress the need for efficacy data obtained from randomized clinical
trials, although they do not insist that cost data be gathered concurrently (2).
A number of papers have discussed the methodologic issues of conducting economic
analyses alongside clinical trials (1;4;9). With the growing experience of conducting eco-
nomic evaluations alongside clinical trials, many methodologic issues are becoming clearer.
These include the identification and exclusion of protocol-driven costs (6;15) and the need
for separate reporting of prices and quantities. However, additional issues are emerging;
many specifically relating to the generalizability of results outside the trial setting (7;16).
Much of the focus of this concern relates to the generalizability of results from country to
country with the predominant view being that economic results may vary due to differences
in healthcare systems, leading to further differences in treatment costs and the accessibility
and use of resources (8;19).
Of equal importance, although little discussed, is the variability in economic outcomes
between treatment centers within countries. Although comparisons of centers within coun-
tries are not subject to differences in healthcare systems, there may still be differences in
both the costs and accessibility of resources. This may make the generalizing of results
based on one treatment center inappropriate. Furthermore, analysis of results from more
than one center may allow identification of more efficient ways to provide therapy.
The aim of this paper is to assess the nature and determinants of variation in costs
between treatment centers using data from a recently conducted study and to discuss the
implications for both the interpretation of published studies and the design of future studies.
METHODS
Clinical Trials
Analysis was conducted on data from two economic evaluations conducted concurrently
with multicenter clinical trials (5;17). The trials compared conventional radiotherapy with
continuous hyperfractionated accelerated radiotherapy (CHART) for patients with head
and neck cancer and with carcinoma of the bronchus. Patients were recruited from 10
participating U.K. centers.
Patients undergoing CHART received three daily treatments over 12 continuous days
compared with the conventional schedule of daily treatments (Monday through Friday over a
6- to 6 12 -week period. Thus, CHART patients require therapy outside of normal radiotherapy
hours and are likely to be hospitalized during the period of therapy, although certain centers
had lower cost hostel wards available for CHART patients.
Study Patients
Data on resource use up to 3 months from study entry were available for 526 head and neck
patients (314 receiving CHART and 212 conventional therapy) and 284 bronchus patients
(175 CHART and 109 conventional therapy).
Cost Data
Data were collected on the use of hospital and community service resources and patient
travel for treatment. For hospital resources, data were collected on the number of bed-days
by ward type, radiotherapy treatments by time of treatment, and outpatient visits. Data were
collected on the number of contacts between the patient and his or her general practitioner,
district nurse, and other community health and social services. Data were also collected on
the number of trips, to and from hospital, the length of the trip, and means of travel.
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Unit cost data for all hospital costs were derived for each participating center. Hospital
travel costs (i.e., ambulance and hospital care) were also derived for each center. Other costs
were derived on a national basis.
Analyses
Analyses were conducted for each of four distinct treatment trial subgroups:
1. Head and neck patients receiving conventional therapy;
2. Head and neck patients receiving CHART;
3. Bronchus patients receiving conventional therapy; and
4. Bronchus patients receiving CHART.
Degree of Variation. First, analysis was conducted to identify the degree of variation
in costs between centers within each subgroup. The statistical significance of differences in
costs between treatment centers was assessed by one-way analysis of variance. This would
allow identification of whether the variation in cost between patients was between or within
centers. The former was of interest for this analysis.
For each treatment trial subgroup in which differences in costs between treatment cen-
ters were statistically significant, analysis was repeated to identify those components of
costs for which there was significant variation between centers. This would allow iden-
tification of which cost components had significant variation between rather than within
centers. Components of costs considered were radiotherapy resource use, other hospital
resource use, community resource use, and travel.
For each analysis, statistical significance was assessed at the 5% level with modified
Bonferroni corrections.
Determinants of Variation. For each of the cost components where variation be-
tween centers was evident, ordinary least-squares regression analysis was conducted to
assess the degree to which variation could be explained by various factors. This would
allow identification of the causes of between-center variation, thus assisting in determining
the generalizability of results and in identifying more efficient clinical practice patterns.
The model attempts to identify the determinants of variation in the cost variance where
the underlying determinants of the costs of an episode of care for the individual patient i
was assumed as:
Ci D 80 C 81Xi ;
where Ci is the individual patient’s cost for care, Xi is a vector of independent variables.
The independent variables within the vector X can be divided into a variable relating to
unit costs (P), a vector of patient characteristics (PC), and a vector of center characteristics.
Center characteristics can be further divided into a vector of identifiable hospital facilities
and services (H) and a vector of treatment center dummy variables (D j ); the coefficient
for each dummy represents unexplained variation in costs between centers. This leaves an
expanded model of the form:
Ci D 90 C 91 PiC92PCi C 93Hi C 94D j i :
All variables were entered into the model, except the dummy variables for the treatment
centers, which were entered in a stepwise fashion. An alternative approach would have been
to adopt a multilevel model with a fixed effects specification whereby all dummy variables
for treatment centers are entered and the intercept term is suppressed (14). However, a
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stepwise approach was necessary; otherwise, the incremental effect of the cost index variable
and hospital characteristics would be undetermined.
The regression models were tested for both omitted variables and for general het-
eroskedasticity. The Ramsey RESET test for heteroskedasticity was employed for each
model, whereby the error term of the original model was regressed against both the square
and the cube of the model’s linear function; the significance of the coefficients of the two
regression variables are used as a test for heteroskedasticity (11). Another form of the
Ramsey RESET test was employed for each model to test for omitted variables. In this test
the square and cube of the linear function are added to the original model, and their level
of significance is a test of the functional form of the model (13).
RESULTS
Degree of Variation
Based on the 95% confidence intervals for mean cost, the degree of variation within each
treatment trial subgroup appears similar (Figure 1). However, the degree of variation be-
tween centers appeared to be greater for the experimental therapy (CHART) than for con-
ventional therapy (Figure 2).
For both the head and neck and bronchus patient trials, there was statistically significant
variation in costs between centers for CHART patients (FD 16.56, p< :001, and FD 16.97,
p< :001, respectively) (Table 1). For conventional therapy, there was greater variation
within centers with no statistically significant variation between centers after Bonferonni
correction. Thus, variation in costs for conventional therapy is likely to be due to patient-
specific rather than center-specific factors.
One-way analysis of variance was subsequently conducted to assess the degree of
variation between centers in the four components of costs for the two CHART trial subgroups
(Table 2). For both the head and neck and bronchus patient trials, there were statistically
significant variations between centers in the costs of radiotherapy (FD 680.07, p< :001,
and FD 668.74, p< :001, respectively) and other hospital resource use (FD 9.07, p< :001,
Figure 1. Mean and 95% confidence interval for total cost by treatment trial subgroup.
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Table 1. One-way Analysis of Variance: Between Centers in Total Costs by Treatment Trial
Subgroups
Head and neck Bronchus
CHART Conventional therapy CHART Conventional therapy
Mean 3,414.67 2,322.54 2,483.54 1,785.75
(SD) (1,697.6) (2,127.8) (912.08) (1,696.5)
F ratio 16.56 2.09 16.97 1.29
(p value) (<.000)a (.032) (<.000)a (0.251)
a Statistical significance of variation between centers assessed at the 5% level with Bonferonni correction.
Figure 2. Mean and 95% confidence interval for total cost by treatment center by treatment
trial subgroup.
and FD 8.71, p< :001, respectively). Variations between centers in the costs of travel and
community resources were not statistically significant.
Determinants of Variation
Table 3 presents definitions for the variables considered for each model. The list of variables
was constrained to the data collected within the clinical trial. Tables 4 and 5 detail the results
of the ordinary least-squares regression analysis to identify factors that are determinants of
the variation in radiotherapy and other hospital costs.
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Table 2. One-way Analysis of Variance: Between Centers in Cost Components for CHART
Patients
Community
Radiotherapy Other hospital Travel resources
Head and neck F ratio 680.07 9.07 2.47 0.86
(p value) (<.000)a (<.000)a (.010) (0.558)
Bronchus F ratio 668.74 8.71 1.21 1.21
(p value) (<.000)a (<.000)a (.294) (.286)
a Statistical significance of variation between centers assessed at the 5% level with Bonferonni correction.
Table 3. Definitions of Potential Variables for Regression Equations
Variable category Variable Definition
Cost data RIND Index of the cost of protocol radiotherapy
regimen
WIND Index of the costs of a hospital ward
bed-day
Patient characteristics AGE Patient’s age
SEX Patient’s gender: maleD 1; femaleD 0
ADV Dummy variable for advanced
tumor (T3 or T4)
WHO Initial WHO status (no restrictionD 0,
restrictedD 1)
Hospital characteristics AMTRT Dummy variable indicating that morning
therapy was given typically outside of
normal hours
HOST Dummy variable indicating that hospital
had hostel provision available
Treatment centers D1,D2 . : : : D10 Dummy variables for each of the treatment
centers
Table 4. Ordinary Least Squares Regression Analysis: Radiotherapy Resource Use
Head and neck Bronchus
Variable Coeff. (t stat) Coeff. (t stat)
Constant 29.75 (0.76) ¡11.27 (0.27)
Cost data
RINDEX 798.90 (46.50) 97.43 (7.36)
Hospital characteristics
AMTRT 190.22 (9.88) 878.07 (75.70)
Patient characteristics
AGE ¡0.74 (1.44) ¡1.08 (1.85)
WHO ¡2.44 (0.21) 10.60 (1.05)
SEX ¡18.74 (1.55) 7.39 (0.62)
ADVANCE ¡16.98 (1.63) ¡11.36 (1.10)
Centers
C3 ¡169.56 (9.39) ¡105.35 (6.95)
C4 100.31 (5.72)
C5 ¡110.14 (4.83) ¡150.90 (7.35)
C6 ¡170.83 (6.71)
C10 ¡57.50 (2.23)
R2 0.974 0.953
See Table 3 for variable definitions.
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Table 5. Ordinary Least Squares Regression Analysis: Other Hospital Resource Use
Head and neck Bronchus
Variable Coeff. (t stat) Coeff. (t stat)
Constant 1,611.57 (2.30) 877.40 (1.82)
Cost data
WINDEX 19.50 (0.05) 735.60 (3.09)
Hospital characteristics
HOSTEL ¡982.93 (5.42) ¡999.37 (7.24)
Patient characteristics
AGE 7.09 (0.97) ¡4.57 (0.85)
WHO 506.17 (3.03) 28.73 (0.30)
SEX ¡148.70 (0.86) ¡239.94 (2.12)
ADVANCE 465.92 (3.11) 176.00 (1.80)
Centers
C2 581.98 (2.90)
C3 666.16 (3.13)
C9 ¡876.13 (3.20)
C10 1,181.06 (2.69)
R2 0.272 0.332
See Table 3 for variable definitions.
For radiotherapy costs, independent variables identified as determinants of variation
were: (a) an index of the cost of protocol radiotherapy regimen, which is a proxy for
overtime payments of staff; and (b) a dummy variable denoting whether the treatment
center the patient was treated at typically gave the morning CHART treatment during
normal working hours (AMTRT). In addition, the coefficients of four dummy variables for
treatment centers were significant for the analysis based on head and neck patients, and three
such variables were significant for the analysis based on bronchus patients. The coefficients
for all other potential variables were not statistically significant and were excluded from
the models.
For other hospital costs, independent variables identified as determinants of variation
were dummy variables denoting whether the treatment center used a hostel ward (HOST)
and whether the patient had an advanced tumor stage of T3 or T4 (ADV). In addition
for bronchus patients, sex was also a significant determinant, as was age for head and
neck patients. In addition, the coefficients of three dummy variables for treatment centers
were significant for the analysis based on head and neck patients, and one such variable
was significant for the analysis based on bronchus patients. The coefficients for all other
potential variables, including an index of the cost of a hospital bed-day, were not statistically
significant and were excluded from the models.
For all models, the Ramsey RESET test showed no significant evidence of heteroskedas-
ticity but did show evidence of omitted variables.
CONCLUSIONS
We explored the issue of the generalizability of results from multicenter economic eval-
uations by examining the degree of variation in costs between centers in two multicenter
randomized controlled trials. The above results identified that significant variation between
centers occurred only in the newer experimental therapy and specifically in relation to ra-
diotherapy and hospital costs. Thus, results based on data from individual centers may not
be generalizable.
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Almost all the variation in radiotherapy costs was explained by differences in unit
costs between centers. This was primarily due to differences in payment mechanisms for
after-hours treatments and the annual use of equipment rather than the quantity of physical
resources used. Thus, unit costs can be seen as a proxy for differences in practices for
providing CHART treatments after hours.
For hospital costs, the provision of hostel accommodation and patient characteristics
were important determinants of variation between treatments. An index variable for hos-
pital bed-day costs was not a significant predictor. Thus, variation appeared to be due to
differences in the provision of services and differences in case mix.
Economic evaluations based on data from more than one treatment center are important
because they can allow for the identification of different hospital practices and differences
in the provision of services, which may influence both the absolute and incremental costs of
treatment. This can then assist in interpolating the study results to other settings and inform
issues surrounding the adoption of the new technology in a given country.
In this analysis, variation in costs by center was greater within the newer experimental
therapy. One interpretation is that treatment centers may, through experience, have identified
the most efficient method for providing conventional therapy but may not have identified
the most efficient method for providing the newer therapy.
A further advantage of studies based on a number of centers is that scenario analysis can
be adopted to provide insight into the likely cost-effectiveness of newer technologies should
all centers adopt the least costly practices. In the case of the CHART clinical trials, adoption
of certain practices within the lower-cost centers would have lessened the incremental cost
of CHART, thus making the incremental cost-effectiveness ratio more attractive.
This highlights the potential benefit of multicenter clinical economic trials in provid-
ing additional information, which may allow more efficient provision of therapy. Thus,
conclusions from studies based on data from only one center may not be generalizable
to other treatment settings, especially when treatment centers are still early on a learning
curve. Within a multicenter evaluation, it may be important to select centers with varying
experience with the experimental therapy to ensure generalizability to as wide a patient
population as possible.
In the trial, data were collected on the use of composite healthcare resources such
as bed-days, outpatient visits, and radiotherapy treatments. If resource use data had been
collected in more minute detail addressing the real variations between centers, such as the
mechanisms of paying staff for each radiotherapy treatment and nursing provision for ward
and hostel bed-days, then calculation of unit costs for each study center may not have been
necessary. Clearly, the costs of such data collection would be excessive and the burden on
any trial both financially and to the patients and data collectors is unlikely to be acceptable.
However, it may be worthwhile that certain center characteristics are recorded to assist in
the interpretation of multicenter data. In addition, given the results of this study, collection
of unit cost data from at least a sample of treatment centers is necessary for all studies based
on a number of treatment centers.
POLICY IMPLICATIONS
The costs of adopting a new health technology can depend critically on precisely how it
is implemented. Where economic evaluations are conducted alongside multicenter clinical
trials, the potential exists to explore the variation of costs by treatment center and to identify
the main local factors affecting costs. This information can be important in policy decisions
about adoption of the new technology, both in assessing the generalizability of study results
and in identifying more efficient clinical practices.
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